Central Nervous System (CNS) Therapeutics Market Size & Share, by Disease (Neurodegenerative, Neurovascular, Mental Health, CNS Trauma, CNS Cancer, Infectious Diseases) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

North America Market Analysis

North America in central nervous system therapeutics market is expected to account for more than 45.4% revenue share by the end of 2037. Factors including well-developed healthcare facilities, a rising geriatric population, and the increasing presence of key players are driving the market growth within the region. As per a report published by the Washington State Department of Health in July 2023, central nervous system stimulants are medications that elevate the activity of norepinephrine and dopamine, resulting in attention, alertness, and energy. For instance, FDA-approved CNS stimulants account for 90% of prescriptions suitable for the treatment of attention-deficit and hyperactivity disorder (ADHD).

The U.S. central nervous system therapeutics market is gaining traction since most people dwell with brain disorders. As stated in the Alzheimer’s Association 2025, almost 7 million people in the U.S. are diagnosed with Alzheimer’s disease. Out of this, approximately 6.9 million belong to the 65-year age group and 73% belong to the 75-year age group and above. Additionally, two-thirds of the U.S. population comprises women suffering from the disease. Thereby, it is projected that by 2050, the patient number will increase to 12.7 million, despite the medical development. Besides, the American Brain Foundation in July 2024 stated that WHO has implemented an action plan to boost brain health and prevent neurological diseases by fostering research, thus positively impacting the market growth.

The central nervous system therapeutics market in Canada is witnessing significant growth owing to the presence of traumatic brain injuries. As disclosed in the Government of Canada 2024 report, concussion is the most common type of such injury, constituting almost 80% to 95%. Moreover, there were 127,460 traumatic-based brain hospitalizations in the region as of 2023, catering to approximately 21,200 per year. Among these, 11% of cases were concussions, 63% were males, 35% were caused due to sports and 29% were due to transport incidents among children, 61% were adults, and 86% were among old patients. To combat this, the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) keeps a check on these issues through demographic and healthcare data, thereby uplifting the market growth.

APAC Market Statistics

The central nervous system therapeutics market in Asia Pacific is the fastest-growing region mental health circumstances pose a significant health challenge. As per the OECD report published in December 2024, an estimated 475 million people are affected by such circumstances, accounting for almost one in seven people. Despite the prevalence, there are considerable treatment gaps due to which 90% of the regional population is devoid of appropriate diagnosis. To overcome this, WHO and OECD have taken measures in the form of community-based health services that are accessible. These services provide education and employment, thus reducing stigma, improving treatment results, and ensuring integrated care.

The central nervous system therapeutics market in India is expecting substantial growth owing to geographical and environmental factors leading to the incidence of neurological diseases. As per the Aging and Health Research March 2024 report, Kashmir has a prevalence rate of 14.1 per 100,000 of Parkinson’s disease in comparison to low prevalence in Bangalore and West Bengal with 27/100,000 and 16.1/100,000 of the disease. However, symptomatic treatment is the only possible treatment solution in the country to aid the disease. This treatment aids the symptoms pertaining to sadness, chorea, obsessiveness, irritability, and other behavioral issues. Through this treatment, palliative care is provided, thereby boosting market growth.

The CNS therapeutics market in China is significantly growing due to the presence of brain cancer. According to a gray model study conducted by NLM in April 2024, the incidence of central nervous system tumors in the region will reach 6.1/100000 people by 2030 and the death rate is projected to be 3.1/100000. However, increasing investment in CNS research, focus on health awareness, and improved hospital treatment and diagnosis are solutions to oppose the disorder. For instance, in August 2024, Mubadala Investment Company stated its partnership with CBC Group and acquired ownership of UCB Pharma’s mature business in the region. The purpose was to expand its CNS drug portfolio in China with healthcare at the forefront of the investment strategy.